Yang, YJ Lee, SH Hong, SJ Chung, BC 2024-01-21T15:11:23Z 2024-01-21T15:11:23Z 2021-09-05 1999-08 0009-9120 https://pubs.kist.re.kr/handle/201004/142035 Objective: The role of dietary fatty acids (FAs) in benign and malignant prostatic diseases was investigated by comparing the composition Value of serum fatty acids in the normal controls, and patients with prostate cancer (PC) and benign prostatic hyperplasia (BPH). Also, to estimate a possible association between PG risk and PUFAs, omega-3, omega-6 and omega-3/omega-6 FA composition ratios were compared among these groups. Methods: Serum samples were obtained from 24 BPH and 19 PC patients, and from 21 age-matched normal male subjects. The serum concentration of 21 fatty acids was determined using gas chromatography/mass spectrometry. Result: The proportional Values of saturated fatty acids (SFAs) groups demonstrated no specific difference between the control subjects and the patients. In the polyunsaturated far, acids (PUFAs), we found that the w-3 PUFAs level was significantly decreased in patient with BPH and PC and that the w-6 PUFAs level was increased in PC only. The ratio of omega-3/omega-6 PUFAs decreased in the following order of normal, BPH, and PC. Conclusion: It was proposed that the changed composition level of PUFAs including omega-3 and w-6 PUFAs have certain relationship with both prostatic diseases. Therefore, the ratio of omega-3/omega-6 PUFAs also may have an important association with the benign and malignant status of prostatic disease. Copyright (C) 1999 The Canadian Society of Clinical Chemists. English PERGAMON-ELSEVIER SCIENCE LTD N-3 PHOSPHOLIPIDS OMEGA-3 GROWTH RISK Comparison of fatty acid profiles in the serum of patients with prostate cancer and benign prostatic hyperplasia Article 10.1016/S0009-9120(99)00036-3 1 CLINICAL BIOCHEMISTRY, v.32, no.6, pp.405 - 409 CLINICAL BIOCHEMISTRY 32 6 405 409 scie scopus 000083512400002 2-s2.0-0005224832 Medical Laboratory Technology Medical Laboratory Technology Article N-3 PHOSPHOLIPIDS OMEGA-3 GROWTH RISK prostate cancer benign prostatic hyperplasia fatty acids gas chromatography/mass spectrometry